Technology
Health
Biotechnology

Synlogic

$7.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.27 (-3.43%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Synlogic and other stocks, options, ETFs, and crypto commission-free!

About

Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. Read More It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Employees
74
Headquarters
Cambridge, Massachusetts
Founded
2017
Market Cap
193.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
117.79K
High Today
$7.85
Low Today
$7.45
Open Price
$7.85
Volume
27.42K
52 Week High
$14.59
52 Week Low
$5.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2015 IPO
US

News

Seeking AlphaMar 12

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2018 Results - Earnings Call Transcript

Synlogic, Inc. (NASDAQ:SYBX) Q4 2016 Results Earnings Conference Call March 12, 2019 8:00 AM ET Company Participants Elizabeth Wolffe - Head, Investor Relations and Corporate Communications Aoife Brennan - President, Chief Executive Officer and Chief Medical Officer Todd Shegog - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Mark Breidenbach - Oppenheimer & Co Inc. Ted Tenthoff - Piper Jaffray & Co. Raghuram Selvaraju - H.C. Wainwright & Co. Joseph Schwartz - S...

19
BusinessWireMar 12

Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2018. “2019 is an exciting year for Synlogic as we continue to advance out platform and programs,” said Aoife Brennan, M.B., Ch.B. Synlogic’s president and chief executive officer. “Data expected mid-year from clinical trials of SYNB1020 and SYNB1618...

5
Seeking AlphaMar 6

Synlogic progressing IBD partnership with AbbVie

Synlogic (NASDAQ:SYBX) has advanced its Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie (NYSE:ABBV) to develop an oral treatment for inflammatory bowel disease (IBD). The companies have been working together on the project since February 2016....

137

Earnings

-$1.66
-$1.25
-$0.84
-$0.43
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.54 per share
Actual
-$0.47 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.